Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Miransertib in PROS and Proteus Syndrome
NCT03094832Phase 2Terminated
- Start
- May 2017
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of miransertib in PIK3CA-related overgrowth spectrum (PROS), Proteus syndrome (PS). Started May 2017; status: terminated.
02
Drugs
miransertib
03
Conditions
PIK3CA-related overgrowth spectrum (PROS)Proteus syndrome (PS)
Beyond the preview
Go deeper on NCT03094832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03094832.